Trial Profile
Addition of Gemcitabine to the Standard Reduced Busulfan and Cyclophosphamide (BUCY2) Pre Allogeneic Hematopoietic Stem Cell Transplantation Conditioning for Acute Lymphoblastic Leukemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Busulfan; Cyclophosphamide
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 30 Jan 2019 Planned End Date changed from 30 Dec 2018 to 1 Sep 2021.
- 30 Jan 2019 Planned primary completion date changed from 30 Sep 2018 to 1 Sep 2020.
- 16 Nov 2017 New trial record